Early detection of myocardial dysfunction and heart failure

Nature Reviews Cardiology

Volumn 7, Issue 6, 2010, Pages 334-344

  De Couto, Geoffrey ^a   Ouzounian, Maral ^a   Liu, Peter P ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COPEPTIN; CYSTATIN C; D DIMER; DNA; FIBRINOGEN; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; HOMOCYSTEINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROADRENOMEDULLIN; RENIN; RNA; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

DIAGNOSTIC ACCURACY; DISEASE COURSE; DOPPLER FLOWMETRY; EARLY DIAGNOSIS; GENETIC SCREENING; GENETIC TRANSCRIPTION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE BIOPSY; HUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RNA TRANSLATION; SEROLOGY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; GALECTIN 3; HEART DISEASES; HEART FAILURE; HUMANS; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TROPONIN;

EID: 77953021953     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.51     Document Type: Review

References (100)

1. Jong, P., Vowinckel, E., Liu, P. P., Gong, Y. & Tu, J. V. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch. Intern. Med. 162, 1689-1694 (2002).
2. Lloyd-Jones, D. et al. Heart disease and stroke statistics--2010 update. A report from the American Heart Association. Circulation 121, e1-e170 (2010).
3. Heo, S., Doering, L. V., Widener, J. & Moser, D. K. Predictors and effect of physical symptom status on health-related quality of life in patients with heart failure. Am. J. Crit. Care 17, 124-132 (2008).
4. Mudd, J. O. & Kass, D. A. Tackling heart failure in the twenty-first century. Nature 451, 919-928 (2008).
5. Heymans, S. et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 11, 119-129 (2009).
6. Goodlin, S. J. Palliative care in congestive heart failure. J. Am. Coll. Cardiol. 54, 386-396 (2009).
7. Bhatia, R. S. et al. Outcome of heart failure with preserved ejection fraction in a populationbased study. N. Engl. J. Med. 355, 260-269 (2006).
8. Tsang, T. S. et al. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J. Am. Coll. Cardiol. 42, 1199-1205 (2003).
9. Redfield, M. M. et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289, 194-202 (2003).
10. Lee, D. S. et al. Antecedent blood pressure, body mass index, and the risk of incident heart failure later in life. Hypertension 50, 869-876 (2007).
11. Turnbull, F. et al. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet 362, 1527-1535 (2003).
12. Yusuf, S. et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340, 1173-1178 (1992).
13. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N. Engl. J. Med. 327, 685-691 (1992).
14. Jong, P., Yusuf, S., Rousseau, M. F., Ahn, S. A. & Bangdiwala, S. I. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 361, 1843-1848 (2003).
15. McDonagh, T. A. et al. Symptomatic and asymptomatic left ventricular dysfunction in an urban population. Lancet 350, 829-833 (1997).
16. Davies, M. K. et al. Prevalence of left ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening Study: a population based study. Lancet 358, 439-444 (2001).
17. Martin, B. J. & Anderson, T. Risk prediction in cardiovascular disease: the prognostic significance of endothelial dysfunction. Can. J. Cardiol. 25 (Suppl. A), 15A-20A (2009).
18. Kubo, S. H., Rector, T. S., Bank, A. J., Williams, R. E. & Heifetz, S. M. Endotheliumdependent vasodilation is attenuated in patients with heart failure. Circulation 84, 1589-1596 (1991).
19. Katz, S. D. et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 111, 310-314 (2005).
20. Morrow, D. A. & de Lemos, J. A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115, 949-952 (2007).
21. Davis, M. et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 343, 440-444 (1994).
22. Maisel, A. et al. State of the art: using natriuretic peptide levels in clinical practice. Eur. J. Heart Fail. 10, 824-839 (2008).
23. Hunt, S. A. et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53, e1-e90 (2009).
24. Dickstein, K. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart Fail. 10, 933-989 (2008).
25. Maisel, A. S. et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347, 161-167 (2002).
26. Mueller, C. et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med. 350, 647-654 (2004). (Pubitemid 38364623)
27. McCullough, P. A. et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106, 416-422 (2002).
28. Brenden, C. K. et al. Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. Am. Heart J. 151, 1006-1011 (2006).
29. de Lemos, J. A., McGuire, D. K. & Drazner, M. H. B-type natriuretic peptide in cardiovascular disease. Lancet 362, 316-322 (2003).
30. Vasan, R. S. et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288, 1252-1259 (2002).
31. Goetze, J. P. et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur. Heart J. 24, 3004-3010 (2006).
32. Horwich, T. B., Hamilton, M. A. & Fonarow, G. C. B-type natriuretic peptide levels in obese patients with advanced heart failure. J. Am. Coll. Cardiol. 47, 85-90 (2006).
33. Latini, R. et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116, 1242-1249 (2007).
34. Tsutamoto, T. et al. Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure. Am. Heart J. 159, 63-67 (2010).
35. Omland, T. et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N. Engl. J. Med. 361, 2538-2547 (2009).
36. Morrow, D. A. & Antman, E. M. Evaluation of highsensitivity assays for cardiac troponin. Clin. Chem. 55, 5-8 (2009).
37. Pepys, M. B. & Hirschfield, G. M. C-reactive protein: a critical update. J. Clin. Invest. 111, 1805-1812 (2003).
38. Verma, S., Szmitko, P. E. & Ridker, P. M. C-reactive protein comes of age. Nat. Clin. Pract. Cardiovasc. Med. 2, 29-36 (2005).
39. Ridker, P. M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103, 1813-1818 (2001).
40. Gottdiener, J. S. et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J. Am. Coll. Cardiol. 35, 1628-1637 (2000).
41. Vasan, R. S. et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107, 1486-1491 (2003).
42. Cesari, M. et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108, 2317-2322 (2003).
43. Kardys, I. et al. C-reactive protein and risk of heart failure. The Rotterdam Study. Am. Heart J. 152, 514-520 (2006).
44. Mueller, C., Laule-Kilian, K., Christ, A., Brunner-La Rocca, H. P. & Perruchoud, A. P. Inflammation and long-term mortality in acute congestive heart failure. Am. Heart J. 151, 845-850 (2006).
45. Anand, I. S. et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112, 1428-1434 (2005).
46. McMurray, J. J. et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 120, 2188-2196 (2009).
47. Kalra, P. R., Anker, S. D. & Coats, A. J. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc. Res. 51, 495-509 (2001).
48. Khan, S. Q. et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115, 2103-2110 (2007).
49. Voors, A. A. et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur. Heart J. 30, 1187-1194 (2009).
50. Stoiser, B. et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur. J. Clin. Invest. 36, 771-778 (2006).
51. Neuhold, S. et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J. Am. Coll. Cardiol. 52, 266-272 (2008).
52. Clerico, A., Del Ry, S. & Giannessi, D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin. Chem. 46, 1529-1534 (2000).
53. Gegenhuber, A. et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin. Chem. 52, 827-831 (2006). (Pubitemid 43673260)
54. von Haehling, S. et al. Comparison of midregional pro-atrial natriuretic peptide with N.-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1973-1980 (2007).
55. Moertl, D. et al. Comparison of midregional proatrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J. Am. Coll. Cardiol. 53, 1783-1790 (2009).
56. Potocki, M. et al. Comparison of midregional proatrial natriuretic peptide with N-terminal pro-Btype natriuretic peptide in the diagnosis of heart failure. J. Intern. Med. 267, 119-129 (2009).
57. Kitamura, K. et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 192, 553-560 (1993). (Pubitemid 23227359)
58. Nishikimi, T. et al. Increased plasma levels of adrenomedullin in patients with heart failure. J. Am. Coll. Cardiol. 26, 1424-1431 (1995).
59. Khan, S. Q. et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J. Am. Coll. Cardiol. 49, 1525-1532 (2007).
60. Adlbrecht, C. et al. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur. J. Heart Fail. 11, 361-366 (2009).
61. Liew, F. Y., Pitman, N. I. & McInnes, I. B. Diseaseassociated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103-110 (2010).
62. Brunner, M. et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. 30, 1468-1473 (2004).
63. Oshikawa, K. et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am. J. Respir. Crit. Care Med. 164, 277-281 (2001).
64. Weinberg, E. O. et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107, 721-726 (2003).
65. Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490 (2005).
66. Sanada, S. et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538-1549 (2007).
67. Shimpo, M. et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109, 2186-2190 (2004).
68. Januzzi, J. L. Jr et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol. 50, 607-613 (2007).
69. Sabatine, M. S. et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117, 1936-1944 (2008).
70. Rehman, S. U., Mueller, T. & Januzzi, J. L. Jr Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 52, 1458-1465 (2008).
71. Pascual-Figal, D. A. et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 54, 2174-2179 (2009).
72. Liu, F. T. & Rabinovich, G. A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29-41 (2005).
73. Sharma, U. C. et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110, 3121-3128 (2004).
74. de Boer, R. A., Voors, A. A., Muntendam, P., van Gilst, W. H. & van Veldhuisen, D. J. Galectin-3: a novel mediator of heart failure development and progression. Eur. J. Heart Fail. 11, 811-817 (2009).
75. van Kimmenade, R. R. et al. Utility of aminoterminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 48, 1217-1224 (2006).
76. Hsiao, E. C. et al. Characterization of growthdifferentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol. Cell Biol. 20, 3742-3751 (2000).
77. Xu, J. et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ. Res. 98, 342-350 (2006).
78. Kempf, T. et al. The transforming growth factorbeta superfamily member growth-differentiation factor-15 protects the heart from ischemia/ reperfusion injury. Circ. Res. 98, 351-360 (2006).
79. Kempf, T. et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1054-1060 (2007).
80. Foley, P. W. et al. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur. Heart J. 30, 2749-2757 (2009).
81. Khan, S. Q. et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur. Heart J. 30, 1057-1065 (2009).
82. Hershberger, R. E., Cowan, J., Morales, A. & Siegfried, J. D. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/ cardiomyopathy. Circ. Heart Fail. 2, 253-261 (2009).
83. Donahue, M. P., Marchuk, D. A. & Rockman, H. A. Redefining heart failure: the utility of genomics. J. Am. Coll. Cardiol. 48, 1289-1298 (2006).
84. Vasan, R. S. et al. Genetic variants associated with cardiac structure and function: a metaanalysis and replication of genome-wide association data. JAMA 302, 168-178 (2009).
85. Wang, T. J. et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 355, 2631-2639 (2006).
86. Zethelius, B. et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med. 358, 2107-2116 (2008).
87. Cooper, L. T. et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. J. Am. Coll. Cardiol. 50, 1914-1931 (2007).
88. van Heerebeek, L. et al. Diastolic stiffness of the failing diabetic heart importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117, 43-51 (2008).
89. Yu, C. M., Sanderson, J. E., Marwick, T. H. & Oh, J. K. Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J. Am. Coll. Cardiol. 49, 1903-1914 (2007).
90. Edvardsen, T., Gerber, B. L., Garot, J., Bluemke, D. A., Lima, J. A. & Smiseth, O. A. Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against three-dimensional tagged magnetic resonance imaging. Circulation 106, 50-56 (2002).
91. Leitman, M. et al. Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function. J. Am. Soc. Echocardiogr. 17, 1021-1029 (2004).
92. Ingul, C. B. et al. Automated analysis of strain rate and strain: feasibility and clinical implications. J.Am. Soc. Echocardiogr. 18, 411-418 (2005).
93. Serri, K. et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 47, 1175-1181 (2006).
94. Saito, K. et al. Comprehensive evaluation of left ventricular strain using speckle tracking echocardiography in normal adults: comparison of three-dimensional and two-dimensional approaches. J. Am. Soc. Echocardiogr. 22, 1025-1030 (2009).
95. Dobrucki, L. W. & Sinusas, A. J. PET and SPECT in cardiovascular molecular imaging. Nat. Rev. Cardiol. 7, 38-47 (2009).
96. Taegtmeyer, H. & Dilsizian, V. Imaging myocardial metabolism and ischemic memory. Nat. Clin. Pract. Cardiovasc. Med. 5 (Suppl. 2), S42-S48 (2008).
97. Lu, E. et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation 108, 97-103 (2003).
98. Meoli, D. F. et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J. Clin. Invest. 113, 1684-1691 (2004).
99. Link, J. M. & Caldwell, J. H. Diagnostic and prognostic imaging of the cardiac sympathetic nervous system. Nat. Clin. Pract. Cardiovasc. Med. 5 (Suppl. 2), S79-S86 (2008).
100. Su, H. et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 112, 3157-3167 (2005).